Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir

ConclusionWhether treatment ‐naïve, treatment‐experienced, or cirrhotic patients with HCV GT 6 residing in the US had excellent outcomes when treated with SOF+VEL or LDV+SOF. Since LDV+SOF is more readily available globally, our results may provide clinicians with a treatment option when cost and availability limit the tr eatment choice.

Source: Alimentary Pharmacology and Therapeutics - November 22, 2018 Category: Drugs & Pharmacology Authors: Emily Nguyen, Sam Trinh, Huy Trinh, Huy Nguyen, Khanh Nguyen, Aivien Do, Brian Levitt, Son Do, My Nguyen, Treta Purohit, Eugenie Shieh, Mindie H. Nguyen Tags: ORIGINAL ARTICLE Source Type: research